Global Tumor NGS Genetic Testing Market Research Report 2024

Publication ID:

PB507247694

Publication Date:

July 12, 2024

Pages:

106

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Tumor NGS Genetic Testing is to use high-throughput sequencing to understand tumors at the genetic level, detect and quantify the genetic components that drive tumors.
The global Tumor NGS Genetic Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Tumor NGS Genetic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Tumor NGS Genetic Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Tumor NGS Genetic Testing in Companion Diagnostics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Tumor NGS Genetic Testing include Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific Inc., DIAN DIAGNOSTICS Group Co., Ltd., Burning Rock Biotech., NovogeneCo.,Ltd., Nanjing Shihejiyin Technology, Inc. and Amoy Diagnostics Co.,Ltd., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Tumor NGS Genetic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor NGS Genetic Testing.
Report Scope
The Tumor NGS Genetic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumor NGS Genetic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor NGS Genetic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific Inc.
DIAN DIAGNOSTICS Group Co., Ltd.
Burning Rock Biotech.
NovogeneCo.,Ltd.
Nanjing Shihejiyin Technology, Inc.
Amoy Diagnostics Co.,Ltd.
China National Pharmaceutical Group Corporation
Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
Guangzhou Kingmed Diagnostics Group Co.,Ltd.
ADICON Clinical Laboratories, Inc.
Genetron
Genecast Group Inc.
BGI Genomics Co.,Ltd.
Beijing-Geneplus Technology Limited.
Xiamen SpacegenCo., Ltd.
骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲.
HaploX
Segment by Type
Liquid Biopsy (Blood Sample)
Tissue Biopsy
Segment by Application
Companion Diagnostics
Early Cancer Screening
Drug Discovery
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor NGS Genetic Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor NGS Genetic Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Liquid Biopsy (Blood Sample)
1.2.3 Tissue Biopsy
1.3 Market by Application
1.3.1 Global Tumor NGS Genetic Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Companion Diagnostics
1.3.3 Early Cancer Screening
1.3.4 Drug Discovery
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor NGS Genetic Testing Market Perspective (2019-2030)
2.2 Tumor NGS Genetic Testing Growth Trends by Region
2.2.1 Global Tumor NGS Genetic Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Tumor NGS Genetic Testing Historic Market Size by Region (2019-2024)
2.2.3 Tumor NGS Genetic Testing Forecasted Market Size by Region (2025-2030)
2.3 Tumor NGS Genetic Testing Market Dynamics
2.3.1 Tumor NGS Genetic Testing Industry Trends
2.3.2 Tumor NGS Genetic Testing Market Drivers
2.3.3 Tumor NGS Genetic Testing Market Challenges
2.3.4 Tumor NGS Genetic Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor NGS Genetic Testing Players by Revenue
3.1.1 Global Top Tumor NGS Genetic Testing Players by Revenue (2019-2024)
3.1.2 Global Tumor NGS Genetic Testing Revenue Market Share by Players (2019-2024)
3.2 Global Tumor NGS Genetic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor NGS Genetic Testing Revenue
3.4 Global Tumor NGS Genetic Testing Market Concentration Ratio
3.4.1 Global Tumor NGS Genetic Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor NGS Genetic Testing Revenue in 2023
3.5 Tumor NGS Genetic Testing Key Players Head office and Area Served
3.6 Key Players Tumor NGS Genetic Testing Product Solution and Service
3.7 Date of Enter into Tumor NGS Genetic Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor NGS Genetic Testing Breakdown Data by Type
4.1 Global Tumor NGS Genetic Testing Historic Market Size by Type (2019-2024)
4.2 Global Tumor NGS Genetic Testing Forecasted Market Size by Type (2025-2030)
5 Tumor NGS Genetic Testing Breakdown Data by Application
5.1 Global Tumor NGS Genetic Testing Historic Market Size by Application (2019-2024)
5.2 Global Tumor NGS Genetic Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Tumor NGS Genetic Testing Market Size (2019-2030)
6.2 North America Tumor NGS Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Tumor NGS Genetic Testing Market Size by Country (2019-2024)
6.4 North America Tumor NGS Genetic Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor NGS Genetic Testing Market Size (2019-2030)
7.2 Europe Tumor NGS Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Tumor NGS Genetic Testing Market Size by Country (2019-2024)
7.4 Europe Tumor NGS Genetic Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor NGS Genetic Testing Market Size (2019-2030)
8.2 Asia-Pacific Tumor NGS Genetic Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Tumor NGS Genetic Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific Tumor NGS Genetic Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor NGS Genetic Testing Market Size (2019-2030)
9.2 Latin America Tumor NGS Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Tumor NGS Genetic Testing Market Size by Country (2019-2024)
9.4 Latin America Tumor NGS Genetic Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor NGS Genetic Testing Market Size (2019-2030)
10.2 Middle East & Africa Tumor NGS Genetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Tumor NGS Genetic Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa Tumor NGS Genetic Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Foundation Medicine
11.1.1 Foundation Medicine Company Detail
11.1.2 Foundation Medicine Business Overview
11.1.3 Foundation Medicine Tumor NGS Genetic Testing Introduction
11.1.4 Foundation Medicine Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.1.5 Foundation Medicine Recent Development
11.2 Guardant Health
11.2.1 Guardant Health Company Detail
11.2.2 Guardant Health Business Overview
11.2.3 Guardant Health Tumor NGS Genetic Testing Introduction
11.2.4 Guardant Health Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.2.5 Guardant Health Recent Development
11.3 Illumina
11.3.1 Illumina Company Detail
11.3.2 Illumina Business Overview
11.3.3 Illumina Tumor NGS Genetic Testing Introduction
11.3.4 Illumina Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.3.5 Illumina Recent Development
11.4 Thermo Fisher Scientific Inc.
11.4.1 Thermo Fisher Scientific Inc. Company Detail
11.4.2 Thermo Fisher Scientific Inc. Business Overview
11.4.3 Thermo Fisher Scientific Inc. Tumor NGS Genetic Testing Introduction
11.4.4 Thermo Fisher Scientific Inc. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.4.5 Thermo Fisher Scientific Inc. Recent Development
11.5 DIAN DIAGNOSTICS Group Co., Ltd.
11.5.1 DIAN DIAGNOSTICS Group Co., Ltd. Company Detail
11.5.2 DIAN DIAGNOSTICS Group Co., Ltd. Business Overview
11.5.3 DIAN DIAGNOSTICS Group Co., Ltd. Tumor NGS Genetic Testing Introduction
11.5.4 DIAN DIAGNOSTICS Group Co., Ltd. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.5.5 DIAN DIAGNOSTICS Group Co., Ltd. Recent Development
11.6 Burning Rock Biotech.
11.6.1 Burning Rock Biotech. Company Detail
11.6.2 Burning Rock Biotech. Business Overview
11.6.3 Burning Rock Biotech. Tumor NGS Genetic Testing Introduction
11.6.4 Burning Rock Biotech. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.6.5 Burning Rock Biotech. Recent Development
11.7 NovogeneCo.,Ltd.
11.7.1 NovogeneCo.,Ltd. Company Detail
11.7.2 NovogeneCo.,Ltd. Business Overview
11.7.3 NovogeneCo.,Ltd. Tumor NGS Genetic Testing Introduction
11.7.4 NovogeneCo.,Ltd. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.7.5 NovogeneCo.,Ltd. Recent Development
11.8 Nanjing Shihejiyin Technology, Inc.
11.8.1 Nanjing Shihejiyin Technology, Inc. Company Detail
11.8.2 Nanjing Shihejiyin Technology, Inc. Business Overview
11.8.3 Nanjing Shihejiyin Technology, Inc. Tumor NGS Genetic Testing Introduction
11.8.4 Nanjing Shihejiyin Technology, Inc. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.8.5 Nanjing Shihejiyin Technology, Inc. Recent Development
11.9 Amoy Diagnostics Co.,Ltd.
11.9.1 Amoy Diagnostics Co.,Ltd. Company Detail
11.9.2 Amoy Diagnostics Co.,Ltd. Business Overview
11.9.3 Amoy Diagnostics Co.,Ltd. Tumor NGS Genetic Testing Introduction
11.9.4 Amoy Diagnostics Co.,Ltd. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.9.5 Amoy Diagnostics Co.,Ltd. Recent Development
11.10 China National Pharmaceutical Group Corporation
11.10.1 China National Pharmaceutical Group Corporation Company Detail
11.10.2 China National Pharmaceutical Group Corporation Business Overview
11.10.3 China National Pharmaceutical Group Corporation Tumor NGS Genetic Testing Introduction
11.10.4 China National Pharmaceutical Group Corporation Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.10.5 China National Pharmaceutical Group Corporation Recent Development
11.11 Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
11.11.1 Shanghai Fosun Pharmaceutical(Group)Co.,Ltd. Company Detail
11.11.2 Shanghai Fosun Pharmaceutical(Group)Co.,Ltd. Business Overview
11.11.3 Shanghai Fosun Pharmaceutical(Group)Co.,Ltd. Tumor NGS Genetic Testing Introduction
11.11.4 Shanghai Fosun Pharmaceutical(Group)Co.,Ltd. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.11.5 Shanghai Fosun Pharmaceutical(Group)Co.,Ltd. Recent Development
11.12 Guangzhou Kingmed Diagnostics Group Co.,Ltd.
11.12.1 Guangzhou Kingmed Diagnostics Group Co.,Ltd. Company Detail
11.12.2 Guangzhou Kingmed Diagnostics Group Co.,Ltd. Business Overview
11.12.3 Guangzhou Kingmed Diagnostics Group Co.,Ltd. Tumor NGS Genetic Testing Introduction
11.12.4 Guangzhou Kingmed Diagnostics Group Co.,Ltd. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.12.5 Guangzhou Kingmed Diagnostics Group Co.,Ltd. Recent Development
11.13 ADICON Clinical Laboratories, Inc.
11.13.1 ADICON Clinical Laboratories, Inc. Company Detail
11.13.2 ADICON Clinical Laboratories, Inc. Business Overview
11.13.3 ADICON Clinical Laboratories, Inc. Tumor NGS Genetic Testing Introduction
11.13.4 ADICON Clinical Laboratories, Inc. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.13.5 ADICON Clinical Laboratories, Inc. Recent Development
11.14 Genetron
11.14.1 Genetron Company Detail
11.14.2 Genetron Business Overview
11.14.3 Genetron Tumor NGS Genetic Testing Introduction
11.14.4 Genetron Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.14.5 Genetron Recent Development
11.15 Genecast Group Inc.
11.15.1 Genecast Group Inc. Company Detail
11.15.2 Genecast Group Inc. Business Overview
11.15.3 Genecast Group Inc. Tumor NGS Genetic Testing Introduction
11.15.4 Genecast Group Inc. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.15.5 Genecast Group Inc. Recent Development
11.16 BGI Genomics Co.,Ltd.
11.16.1 BGI Genomics Co.,Ltd. Company Detail
11.16.2 BGI Genomics Co.,Ltd. Business Overview
11.16.3 BGI Genomics Co.,Ltd. Tumor NGS Genetic Testing Introduction
11.16.4 BGI Genomics Co.,Ltd. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.16.5 BGI Genomics Co.,Ltd. Recent Development
11.17 Beijing-Geneplus Technology Limited.
11.17.1 Beijing-Geneplus Technology Limited. Company Detail
11.17.2 Beijing-Geneplus Technology Limited. Business Overview
11.17.3 Beijing-Geneplus Technology Limited. Tumor NGS Genetic Testing Introduction
11.17.4 Beijing-Geneplus Technology Limited. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.17.5 Beijing-Geneplus Technology Limited. Recent Development
11.18 Xiamen SpacegenCo., Ltd.
11.18.1 Xiamen SpacegenCo., Ltd. Company Detail
11.18.2 Xiamen SpacegenCo., Ltd. Business Overview
11.18.3 Xiamen SpacegenCo., Ltd. Tumor NGS Genetic Testing Introduction
11.18.4 Xiamen SpacegenCo., Ltd. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.18.5 Xiamen SpacegenCo., Ltd. Recent Development
11.19 骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲.
11.19.1 骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲. Company Detail
11.19.2 骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲. Business Overview
11.19.3 骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲. Tumor NGS Genetic Testing Introduction
11.19.4 骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲. Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.19.5 骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲. Recent Development
11.20 HaploX
11.20.1 HaploX Company Detail
11.20.2 HaploX Business Overview
11.20.3 HaploX Tumor NGS Genetic Testing Introduction
11.20.4 HaploX Revenue in Tumor NGS Genetic Testing Business (2019-2024)
11.20.5 HaploX Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific Inc.
DIAN DIAGNOSTICS Group Co., Ltd.
Burning Rock Biotech.
NovogeneCo.,Ltd.
Nanjing Shihejiyin Technology, Inc.
Amoy Diagnostics Co.,Ltd.
China National Pharmaceutical Group Corporation
Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
Guangzhou Kingmed Diagnostics Group Co.,Ltd.
ADICON Clinical Laboratories, Inc.
Genetron
Genecast Group Inc.
BGI Genomics Co.,Ltd.
Beijing-Geneplus Technology Limited.
Xiamen SpacegenCo., Ltd.
骋别苍别颈蝉锛圔别颈箩颈苍驳锛塁辞.尝迟诲.
HaploX

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂